Literature DB >> 23205179

Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.

Jennifer C Melvin1, Crystal Rodrigues, Lars Holmberg, Hans Garmo, Niklas Hammar, Ingmar Jungner, Göran Walldius, Mats Lambe, Wayel Jassem, Mieke Van Hemelrijck.   

Abstract

BACKGROUND: Recent studies suggested that gamma-glutamyl transferase (GGT) and C-reactive protein (CRP) are good markers of metabolic abnormalities. We assessed the link between GGT, CRP and common metabolic abnormalities, as well their link to related diseases, such as cancer and cardiovascular disease (CVD).
METHODS: We selected 333,313 subjects with baseline measurements of triglycerides (TG), total cholesterol (TC), glucose, GGT and CRP in the Swedish AMORIS study. Baseline measurement of BMI was available for 63,900 persons and 77,944 had baseline measurements of HDL. Pearson correlation coefficients between CRP, GGT, and metabolic components (TG, HDL, BMI and TC) were calculated. To investigate the combined effect of GGT and CRP we created a score ranging from 0 to 6 and used Cox proportional hazard models to evaluate its association with CVD and cancer.
RESULTS: 21,216 individuals developed cancer and 47,939 CVD. GGT and TG had the strongest correlation (r=0.22). An increased risk of cancer was identified with elevated levels of GGT or CRP or both markers (GGT-CRP score ≥3); the greatest risk of cancer was found when GGT-CRP score = 6 (HR: 1.40 (95%CI: 1.31-1.48) and 1.60 (1.47-1.76) compared to GGT-CRP score = 0, respectively).
CONCLUSION: While GGT and CRP have been shown to be associated with metabolic abnormalities previously, their association to the components investigated in this study was limited. Results did demonstrate that these markers were predictive of associated diseases, such as cancer.

Entities:  

Keywords:  CRP; GGT; cancer; cardiovascular disease; metabolic abnormalities

Year:  2012        PMID: 23205179      PMCID: PMC3508539     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  40 in total

1.  Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females.

Authors:  I Jungner; G Walldius; I Holme; W Kolar; E Steiner
Journal:  Int J Clin Lab Res       Date:  1992

2.  Rapid automated high sensitivity enzyme immunoassay of C-reactive protein.

Authors:  J Wilkins; J R Gallimore; E G Moore; M B Pepys
Journal:  Clin Chem       Date:  1998-06       Impact factor: 8.327

3.  The metabolic syndrome and concentrations of C-reactive protein among U.S. youth.

Authors:  Earl S Ford; Umed A Ajani; Ali H Mokdad
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

4.  Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

Authors:  Ingar Holme; Are H Aastveit; Niklas Hammar; Ingmar Jungner; Göran Walldius
Journal:  Atherosclerosis       Date:  2010-08-19       Impact factor: 5.162

5.  High sensitivity C-reactive protein as an independent risk factor for essential hypertension.

Authors:  Ki Chul Sung; Jung Yul Suh; Bum Soo Kim; Jin Ho Kang; Hyang Kim; Man Ho Lee; Jung Ro Park; Sun Woo Kim
Journal:  Am J Hypertens       Date:  2003-06       Impact factor: 2.689

6.  Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer.

Authors:  Jiyoung Ahn; Unhee Lim; Stephanie J Weinstein; Arthur Schatzkin; Richard B Hayes; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11-03       Impact factor: 4.254

7.  Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study.

Authors:  Alexander M Strasak; Kilian Rapp; Larry J Brant; Wolfgang Hilbe; Martin Gregory; Willi Oberaigner; Elfriede Ruttmann; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

8.  The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes.

Authors:  S G Wannamethee; L Lennon; A G Shaper
Journal:  Atherosclerosis       Date:  2008-03-10       Impact factor: 5.162

9.  Metabolic syndrome and cancer risk.

Authors:  Antonio Russo; Mariangela Autelitano; Luigi Bisanti
Journal:  Eur J Cancer       Date:  2007-12-04       Impact factor: 9.162

10.  High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons.

Authors:  Ryuichi Kawamoto; Yasuharu Tabara; Katsuhiko Kohara; Tetsuro Miki; Tomo Kusunoki; Shuzo Takayama; Masanori Abe; Tateaki Katoh; Nobuyuki Ohtsuka
Journal:  Cardiovasc Diabetol       Date:  2010-12-09       Impact factor: 9.951

View more
  5 in total

1.  Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.

Authors:  Lydia Shackshaft; Mieke Van Hemelrijck; Hans Garmo; Håkan Malmström; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Wahyu Wulaningsih
Journal:  Breast Cancer Res       Date:  2017-03-06       Impact factor: 6.466

2.  MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits.

Authors:  Erik Taylor; Nasi Huang; Jacob Bodde; Andrew Ellison; Ronald Killiany; Markus Michael Bachschmid; James Hamilton
Journal:  J Transl Med       Date:  2018-08-01       Impact factor: 5.531

3.  Risk of gastrointestinal cancer in patients with an elevated level of gamma-glutamyltransferase: A nationwide population-based study.

Authors:  Seung Wook Hong; Hyun Jung Lee; Kyungdo Han; Jung Min Moon; Seona Park; Hosim Soh; Eun Ae Kang; Jaeyoung Chun; Jong Pil Im; Joo Sung Kim
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

4.  Gamma glutamyl transferases in association with cardiovascular risk scores in non-diabetic hypertensive Cameroonians: preliminary data from HYRICCA study.

Authors:  Jan René Nkeck; Chemgne Marie Ida; Valerie Ndobo Koe; Antonin Wilson Ndjitoyap Ndam; Yondo Ndedi Claudine Jessica; Eko Ondoa Manuella; Boukeu Yonta Charelle; Zouague Zalbi Corine; Ntyam Abena Andrée; Falmata Amazia; Jériel Pascal Nkeck; Esther Astrid Mbono Samba; Vicky Jocelyne Ama Moor
Journal:  BMC Res Notes       Date:  2022-09-15

5.  Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study.

Authors:  Cecilia Bosco; Wahyu Wulaningsih; Jennifer Melvin; Aida Santaolalla; Mario De Piano; Rhonda Arthur; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2015-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.